2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery.
This study aimed to investigate the mechanisms involved in the contractile effects produced by the novel quinoline derivative, 2-(2-aminoethyl)-quinoline (D-1997), in the canine isolated basilar artery. For comparison, the effects of D-1997 were also evaluated on rat aorta. Canine basilar artery and rat aortic rings were prepared and mounted in organ baths to record isometric tension changes. The contractile effects of D-1997 in the basilar artery were compared with those produced by 5-hydroxytryptamine (5-HT) and the 5-HT receptor agonist quipazine. Thus, 4-HT (10(-10)-10(-6)M), D-1997 (3.1 x 10(-8)-10(-4) M) and quipazine (3.1 x 10(-7)-10(-4) M) each caused concentration-dependent contractions of the canine basilar artery with a rank order of agonist potency of 5-HT > D-1997 > quipazine. 5-HT and D-1997 exhibited similar maximum effects which were higher than that of quipazine. Similar concentrations of D-1997 failed to produce contraction in rat aorta. The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM). In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and 5-HT2 receptor antagonist methiothepin (0.01-1 microM). It is concluded that D-1997 contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or 5-HT1B receptor subtypes. The compound seems to be devoid of 5-HT2 receptor agonist properties in rat aorta.
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13 T14 T15 T16 T17 T18 T19 T20 T21 T22 T23 T24 T25 T26 T27 T28 T29 T30 T31 T32 T33 T34 T35 T36 T37 T38 T39 T40 T41 T42 T43 T44 T45 T46 T47
CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL GENE-N GENE-N GENE-Y GENE-Y GENE-N GENE-Y GENE-Y GENE-N GENE-N GENE-N GENE-N GENE-Y GENE-Y GENE-N GENE-N GENE-N
quinoline ketanserin tropisetron spiroxatrine 2-(2-aminoethyl)-quinoline (+/-)-pindolol prazosin D-1997 D-1997 methiothepin D-1997 D-1997 D-1997 5-hydroxytryptamine 5-HT 5-HT quipazine 4-HT D-1997 quipazine 5-HT D-1997 quipazine 5-HT D-1997 quipazine D-1997 D-1997 2-(2-Aminoethyl)-quinoline D-1997 5-hydroxytryptamine 5-HT2 receptor 5-HT3 5-HT4 5-HT1A beta-adrenoceptor 5-HT1A 5-HT1B alpha 1-adrenoceptor 5-HT1-like 5-HT2 receptor 5-HT1-like receptors 5-HT1A 5-HT1B 5-HT2 receptor 5-HT receptor 5-hydroxytryptamine1-like receptors